Dr. Vavvas is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
243 Charles St
Boston, MA 02114Phone+1 617-573-5589
Education & Training
- Massachusetts Eye and Ear Infirmary/Harvard Medical SchoolChief Residency, Ophthalmology, 2003 - 2004
- Massachusetts Eye and Ear Infirmary/Harvard Medical SchoolResidency, Ophthalmology, 2000 - 2004
- Boston University Medical CenterInternship, Internal Medicine, 1999 - 2000
- Boston University School of MedicineClass of 1999
- Massachusetts Eye and Ear Infirmary/Harvard Medical SchoolFellowship, Surgical Retina and Vitreous
- McGill UniversityB.Sc., Biology/ Neuroscience, First Class Honors
Certifications & Licensure
- MA State Medical License 2003 - 2026
- American Board of Ophthalmology Ophthalmology
Clinical Trials
- Therapeutic Contact Lens Drug Delivery System (TCL-DDS) in Patients With Recurrent Cystoid Macular Edema Start of enrollment: 2021 Mar 15
Publications & Presentations
PubMed
- 55 citationsStructural Changes Associated with Delayed Dark Adaptation in Age-Related Macular Degeneration.Inês Laíns, John B Miller, Dong H. Park, Edem Tsikata, Samaneh Davoudi
Ophthalmology. 2017-09-01 - 4 citationsArea under the dark adaptation curve as a reliable alternate measure of dark adaptation response.Shrinivas Pundlik, Archana Nigalye, Inês Laíns, Kevin M. Mendez, Raviv Katz
The British Journal of Ophthalmology. 2021-04-22 - 143 citationsSubretinal Hyperreflective Material in the Comparison of Age-Related Macular Degeneration Treatments TrialsAlex S. Willoughby, Gui-Shuang Ying, Cynthia A. Toth, Maureen G. Maguire, Russell Burns
Ophthalmology. 2015-09-01
Journal Articles
- Permanent Neuroglial Remodeling of the Retina Following Infiltration of CSF1R Inhibition-Resistant Peripheral MonocytesClaes H Dohlman, James Chodosh, Demetrios G Vavvas, Reza Dana, Proceedings of the National Academy of Sciences
Press Mentions
- Apellis’ Syfovre Approved as First Treatment for Geographic Atrophy Despite Uncertain Clinical BenefitMarch 7th, 2023
- Apellis Wins FDA Approval of First Drug for Type of Vision LossFebruary 17th, 2023
- RETINA CONVERSATIONS: A Conversation with Evangelos S. Gragoudas, MDMarch 1st, 2019
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: